{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:35:59Z","timestamp":1794072959635,"version":"4.8.0"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,11,1]],"date-time":"2018-11-01T00:00:00Z","timestamp":1541030400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"National Key Basic Research Program of China","award":["2013CB966800"],"award-info":[{"award-number":["2013CB966800"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670127"],"award-info":[{"award-number":["81670127"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81101721"],"award-info":[{"award-number":["81101721"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81123005"],"award-info":[{"award-number":["81123005"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81170531"],"award-info":[{"award-number":["81170531"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["16PJ1406100"],"award-info":[{"award-number":["16PJ1406100"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003399","name":"Science and Technology Commission of Shanghai Municipality","doi-asserted-by":"publisher","award":["16ZR1421000"],"award-info":[{"award-number":["16ZR1421000"]}],"id":[{"id":"10.13039\/501100003399","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novo Nordisk Hemophilia Research Fund in China"},{"DOI":"10.13039\/501100004731","name":"Zhejiang Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["LY17H080004"],"award-info":[{"award-number":["LY17H080004"]}],"id":[{"id":"10.13039\/501100004731","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Blood Cells, Molecules, and Diseases"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1016\/j.bcmd.2018.09.004","type":"journal-article","created":{"date-parts":[[2018,9,20]],"date-time":"2018-09-20T20:44:36Z","timestamp":1537476276000},"page":"47-54","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo"],"prefix":"10.1016","volume":"73","author":[{"given":"Wei","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianhua","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ruan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenman","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saijuan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weidong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Xi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcmd.2018.09.004_bb0005","doi-asserted-by":"crossref","first-page":"11","DOI":"10.18388\/abp.2015_1056","article-title":"The factor VIII protein and its function","volume":"63","author":"Mazurkiewicz-Pisarek","year":"2016","journal-title":"Acta Biochim. Pol."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0010","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1111\/j.1365-2516.2012.02909.x","article-title":"Guidelines for the management of hemophilia","volume":"19","author":"Srivastava","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0015","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias\u2013from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0020","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"issue":"Suppl. 4","key":"10.1016\/j.bcmd.2018.09.004_bb0025","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1365-2516.2004.00984.x","article-title":"Preclinical and clinical gene therapy for haemophilia","volume":"10","author":"Chuah","year":"2004","journal-title":"Haemophilia"},{"issue":"Suppl. 1","key":"10.1016\/j.bcmd.2018.09.004_bb0030","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/ijlh.12659","article-title":"Factor VIII inhibitors: advances in basic and translational science","volume":"39","author":"Lai","year":"2017","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0035","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/1521-2254(200101\/02)3:1<3::AID-JGM167>3.0.CO;2-H","article-title":"Gene therapy for hemophilia","volume":"3","author":"Chuah","year":"2001","journal-title":"J. Gene Med."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0040","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1046\/j.1538-7836.2003.00096.x","article-title":"A single adeno-associated virus (AAV)-murine factor VIII vector partially corrects the hemophilia A phenotype","volume":"1","author":"Sarkar","year":"2003","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0045","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1089\/hum.2006.17.427","article-title":"Long-term efficacy of adeno-associated virus serotypes 8 and 9 in hemophilia a dogs and mice","volume":"17","author":"Sarkar","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0050","doi-asserted-by":"crossref","first-page":"3846","DOI":"10.1182\/blood.V88.10.3846.bloodjournal88103846","article-title":"Complete short-term correction of canine hemophilia A by in vivo gene therapy","volume":"88","author":"Connelly","year":"1996","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0055","doi-asserted-by":"crossref","first-page":"10379","DOI":"10.1073\/pnas.96.18.10379","article-title":"Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice","volume":"96","author":"VandendDriessche","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0060","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1016\/j.hoc.2017.06.011","article-title":"Gene therapy for hemophilia","volume":"31","author":"Nathwani","year":"2017","journal-title":"Hematol. Oncol. Clin. North Am."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0065","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMoa1708483","article-title":"AAV5-factor VIII gene transfer in severe hemophilia A","volume":"377","author":"Rangarajan","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"Suppl. 5","key":"10.1016\/j.bcmd.2018.09.004_bb0070","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/hae.13011","article-title":"State of the art: gene therapy of haemophilia","volume":"22","author":"Spencer","year":"2016","journal-title":"Haemophilia"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0075","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.blre.2015.03.002","article-title":"Haemophilia gene therapy: Progress and challenges","volume":"29","author":"Lheriteau","year":"2015","journal-title":"Blood Rev."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0080","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","article-title":"Gene therapy for hemophilia","volume":"25","author":"Nienhuis","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0085","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1182\/blood-2010-05-282707","article-title":"Codon optimization of human factor VIII cDNAs leads to high-level expression","volume":"117","author":"Ward","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0090","doi-asserted-by":"crossref","first-page":"3335","DOI":"10.1182\/blood-2012-10-462200","article-title":"Therapeutic levels of FVIII following a single peripheral vein administration of rAAV vector encoding a novel human factor VIII variant","volume":"121","author":"McIntosh","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0095","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1538-7836.2006.02283.x","article-title":"Disulfide bond-stabilized factor VIII has prolonged factor VIIIa activity and improved potency in whole blood clotting assays","volume":"5","author":"Radtke","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0100","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1111\/j.1538-7836.2006.01951.x","article-title":"Intrinsic stability and functional properties of disulfide bond-stabilized coagulation factor VIIIa variants","volume":"4","author":"Gale","year":"2006","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/jth.13543","article-title":"Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A","volume":"15","author":"Nguyen","year":"2017","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0110","doi-asserted-by":"crossref","first-page":"11851","DOI":"10.1073\/pnas.94.22.11851","article-title":"Characterization of a genetically engineered inactivation-resistant coagulation factor VIIIa","volume":"94","author":"Pipe","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0115","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1182\/blood-2012-10-464164","article-title":"Minimal modification in the factor VIII B-domain sequence ameliorates the murine hemophilia A phenotype","volume":"121","author":"Siner","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0120","doi-asserted-by":"crossref","first-page":"38345","DOI":"10.1074\/jbc.M206959200","article-title":"High level expression of recombinant porcine coagulation factor VIII","volume":"277","author":"Doering","year":"2002","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0125","doi-asserted-by":"crossref","first-page":"6546","DOI":"10.1074\/jbc.M312451200","article-title":"Identification of porcine coagulation factor VIII domains responsible for high level expression via enhanced secretion","volume":"279","author":"Doering","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0130","doi-asserted-by":"crossref","first-page":"4562","DOI":"10.1182\/blood-2009-05-220327","article-title":"Recombinant canine B-domain-deleted FVIII exhibits high specific activity and is safe in the canine hemophilia A model","volume":"114","author":"Sabatino","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0135","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1038\/gt.2016.34","article-title":"Evaluation of the biological differences of canine and human factor VIII in gene delivery: implications in human hemophilia treatment","volume":"23","author":"Wang","year":"2016","journal-title":"Gene Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0140","first-page":"319","article-title":"Current status of gene therapy for hemophilia","volume":"2","author":"Nathwani","year":"2003","journal-title":"Curr. Hematol. Rep."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0145","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1089\/104303403321070838","article-title":"Dual vectors expressing murine factor VIII result in sustained correction of hemophilia A mice","volume":"14","author":"Mah","year":"2003","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0150","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1089\/hgtb.2014.093","article-title":"Efficient production of dual recombinant adeno-associated viral vectors for factor VIII delivery","volume":"25","author":"Wang","year":"2014","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0155","doi-asserted-by":"crossref","first-page":"12725","DOI":"10.1073\/pnas.96.22.12725","article-title":"Coexpression of factor VIII heavy and light chain adeno-associated viral vectors produces biologically active protein","volume":"96","author":"Burton","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0160","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1007\/s11427-013-4455-7","article-title":"Inter-chain disulfide bond improved protein trans-splicing increases plasma coagulation activity in C57BL\/6 mice following portal vein FVIII gene delivery by dual vectors","volume":"56","author":"Zhu","year":"2013","journal-title":"Sci. China Life Sci."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0165","doi-asserted-by":"crossref","first-page":"3919","DOI":"10.1182\/blood-2003-01-0222","article-title":"Phenotypic correction of a mouse model of hemophilia A using AAV2 vectors encoding the heavy and light chains of FVIII","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0170","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1038\/mt.2009.258","article-title":"Characterization of genome integrity for oversized recombinant AAV vector","volume":"18","author":"Dong","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0175","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.bcmd.2015.06.002","article-title":"Clinical features and molecular basis of 102 Chinese patients with congenital dysfibrinogenemia","volume":"55","author":"Zhou","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0180","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1111\/bjh.13797","article-title":"New products for the treatment of haemophilia","volume":"172","author":"Laffan","year":"2016","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0185","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1111\/bjh.13360","article-title":"Role of enhanced half-life factor VIII and IX in the treatment of haemophilia","volume":"169","author":"Mahdi","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0190","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1111\/j.1538-7836.2005.01401.x","article-title":"Gene therapy for hemophilia: an imperative to succeed","volume":"3","author":"Hough","year":"2005","journal-title":"J. Thromb. Haemost."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0195","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1089\/hum.2008.150","article-title":"Comparison of factor VIII transgenes bioengineered for improved expression in gene therapy of hemophilia A","volume":"20","author":"Dooriss","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0200","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1038\/mt.2010.240","article-title":"Efficacy and safety of long-term prophylaxis in severe hemophilia A dogs following liver gene therapy using AAV vectors","volume":"19","author":"Sabatino","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0205","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0049481","article-title":"Development and characterization of recombinant ovine coagulation factor VIII","volume":"7","author":"Zakas","year":"2012","journal-title":"PLoS One"},{"issue":"4","key":"10.1016\/j.bcmd.2018.09.004_bb0210","first-page":"373","article-title":"Enhancing effect of porcine coagulation factor VIII A1 and A3 domains on secretion of post-translationally spliced human\/porcine hybrid coagulation factor VIII","volume":"62","author":"Zhu","year":"2010","journal-title":"Acta Phys. Sin."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0215","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1038\/sj.mt.6300268","article-title":"The enhancing effects of the light chain on heavy chain secretion in split delivery of factor VIII gene","volume":"15","author":"Chen","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0220","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/mt.2008.292","article-title":"Enhanced factor VIII heavy chain for gene therapy of hemophilia A","volume":"17","author":"Chen","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0225","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1182\/blood-2003-08-2954","article-title":"Total correction of hemophilia A mice with canine FVIII using an AAV 8 serotype","volume":"103","author":"Sarkar","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0230","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1182\/blood-2005-12-5115","article-title":"Multiyear therapeutic benefit of AAV serotypes 2, 6, and 8 delivering factor VIII to hemophilia A mice and dogs","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0235","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1182\/blood-2003-01-0292","article-title":"Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector","volume":"102","author":"Scallan","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.bcmd.2018.09.004_bb0240","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcmd.2018.09.004_bb0245","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1056\/NEJMoa1108046","article-title":"Adenovirus-associated virus vector-mediated gene transfer in hemophilia B","volume":"365","author":"Nathwani","year":"2011","journal-title":"N. Engl. J. Med."}],"container-title":["Blood Cells, Molecules, and Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961830233X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S107997961830233X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T12:33:06Z","timestamp":1761049986000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S107997961830233X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11]]},"references-count":49,"alternative-id":["S107997961830233X"],"URL":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.09.004","relation":{},"ISSN":["1079-9796"],"issn-type":[{"value":"1079-9796","type":"print"}],"subject":[],"published":{"date-parts":[[2018,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the activity levels of rat FVIII and human FVIII delivered by adeno-associated viral vectors both in vitro and in vivo","name":"articletitle","label":"Article Title"},{"value":"Blood Cells, Molecules, and Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcmd.2018.09.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}